There are several oral SERDs currently in clinical development for ER+/HER2− breast cancer, of which elacestrant (RAD1901), camizestrant (AZD9833), giredestrant (GDC-9545), and imlunestrant (LY3484356) are now in Phase 3 trials. This evidence concerns the gene ESR1 and breast carcinoma.